Medpace Holdings, Inc. $MEDP Stake Trimmed by Fundsmith LLP

Fundsmith LLP cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 52,372 shares of the company’s stock after selling 10,296 shares during the period. Medpace comprises 0.2% of Fundsmith LLP’s holdings, making the stock its 26th largest position. Fundsmith LLP’s holdings in Medpace were worth $27,736,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Johnson Financial Group Inc. purchased a new stake in shares of Medpace in the 2nd quarter valued at approximately $27,000. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp purchased a new position in shares of Medpace during the second quarter valued at $30,000. Finally, Allied Private Wealth LLC purchased a new position in shares of Medpace during the second quarter valued at $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of Medpace stock opened at $600.65 on Monday. The company’s fifty day simple moving average is $565.33 and its 200-day simple moving average is $494.30. The company has a market cap of $16.76 billion, a price-to-earnings ratio of 35.21, a PEG ratio of 2.68 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the company earned $3.10 EPS. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MEDP. Mizuho raised their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Royal Bank Of Canada increased their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. BMO Capital Markets raised their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Finally, Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $584.18.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 27,174 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the sale, the chief executive officer owned 561,195 shares in the company, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 133,821 shares of company stock valued at $81,748,135. 20.50% of the stock is currently owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.